{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63"}]}],"title":"AST, G0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"AST, G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"AST, G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"AST, G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"AST, G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"67"}]}],"title":"ALT, G0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"ALT, G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"ALT, G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"ALT, G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"ALT, G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"80"}]}],"title":"Total Bilirubin, G0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Total Bilirubin, G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Total Bilirubin, G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Total Bilirubin, G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Total Bilirubin, G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"85"}]}],"title":"Albumin, G0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Albumin, G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Albumin, G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Albumin, G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Albumin, G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"67"}]}],"title":"ALP, G0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"ALP, G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"ALP, G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"ALP, G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"ALP, G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"72"}]}],"title":"Creatinine, G0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"Creatinine, G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Creatinine, G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Creatinine, G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Creatinine, G4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"description":"Clinical chemistry parameters were summarized according to the NCI CTCAE, version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Clinical chemistry parameters included: AST, ALP, total bilirubin, albumin, ALT, and creatinine. For participants randomized to Placebo in Part 1, the BL value for Part 2 is defined as the value taken at Week 13 of Part 1. For serum creatinine, the value taken at Week 13 of Part 1 will be used as BL. For participants randomized to Eltrombopag in Part 1, the BL value is defined as the value taken on Day 1 or, if missing, the latest non-missing Screening value. For serum creatinine, due to the variations in creatinine, the average of the Screening and the Day 1 values will be used as BL. For participants who do not have both a Screening and Day 1 value, the Screening or Day 1 value will be used as BL. The maximum post-BL toxicity grade includes any scheduled or unscheduled post-BL assessment.","groups":[{"description":"Participants who received eltrombopag in Part 1 continued on the same dose in Part 2 unless adjustments were warranted according to the dosing guidelines. Participants who received placebo in Part 1 received Eltrombopag as per age criteria as follows: aged between 6 and 17 years with a body weight \\<27 kg received eltrombopag 37.5 mg QD, and those with a body weight \\>=27 kg received eltrombopag 50 mg QD. Participants of East Asian ancestry received a starting dose of eltrombopag 25 mg QD. Participants aged between 1 and 5 years received eltrombopag 1.2 mg/kg QD and; participants of East Asian ancestry received a starting dose of eltrombopag 0.8 mg/kg/day.","id":"OG000","title":"Part 2 (Open-Label Period) - Eltrombopag"}],"paramType":"NUMBER","populationDescription":"Safety Population. Only those participants who entered into Part 2 (Open-label eltrombopag-only phase) were analyzed.","reportingStatus":"POSTED","timeFrame":"From Baseline (BL) of Part 2 through Follow-up","title":"Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During Part 2","type":"SECONDARY","unitOfMeasure":"Participants"}